Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
-
Child's play for Haaland as Man City star strikes again
-
India crush Pakistan by 88 runs amid handshake snub, umpiring drama
-
Hojlund fires Napoli past Genoa and into Serie A lead
-
Sevilla rout 'horrendous' Barca in Liga thrashing
-
Haaland fires Man City to win at Brentford, Everton end Palace's unbeaten run
-
Haaland extends hot streak as Man City sink Brentford
-
Italy working hard to prevent extra US tariffs on pasta
-
Sinner out of Shanghai Masters as Djokovic battles into last 16
-
Swift rules N. America box office with 'Showgirl' event
-
Ryder Cup hero MacIntyre wins Alfred Dunhill Links on home soil
-
Republicans warn of pain ahead as US shutdown faces second week
-
Sevilla rout champions Barca in shock Liga thrashing
-
Norris-Piastri clash overshadows McLaren constructors' title win
-
Trump administration declares US cities war zones
-
Bad Bunny takes aim at Super Bowl backlash in 'SNL' host gig
-
El Khannouss fires Stuttgart into Bundesliga top four
-
Insatiable Pogacar romps to European title
-
Newcastle inflict more pain on Postecoglou, Everton end Palace's unbeaten run
-
Daryz wins emotional and thrilling Prix de l'Arc de Triomphe
-
US Open finalist Anisimova wins Beijing title in 'great year'
-
Daryz wins Prix de l'Arc de Triomphe thriller
-
Russell wins Singapore GP as McLaren seal constructors' title
-
Landslides and floods kill 64 in Nepal, India
-
Russell wins Singapore GP, McLaren seal constructors' title
-
Djokovic 'hangs by rope' before battling into Shanghai last 16
-
Erasmus proud of Boks' title triumph as Rugby Championship faces uncertain future
-
US Open finalist Anisimova caps breakthrough year with Beijing title
-
French PM under pressure to put together cabinet
-
US Open finalist Anisimova beats Noskova to win Beijing title
-
Hamas calls for swift hostage-prisoner swap as talks set to begin
-
Opec+ plus to raise oil production by 137,000 barrels a day in November
-
Death toll from Indonesia school collapse rises to 45
-
Brisbane Broncos edge Storm in thrilling NRL grand final
-
Hamas calls for swift prisoner release as talks set to begin
-
Refreshed Sabalenka 'ready to go' after post-US Open break
-
Marquez fears 'something is broken' as world champion hurt in crash
-
Georgia PM vows sweeping crackdown after 'foiled coup'
-
Landslides and floods kill 63 in Nepal, India
-
No handshakes again as India, Pakistan meet at Women's World Cup
-
Georgia PM announces sweeping crackdown on opposition after 'foiled coup'
-
Syria selects members of first post-Assad parliament
-
Russian strikes kill five in Ukraine, cause power outages
-
World champion Marquez crashes out as Aldeguer wins Indonesia MotoGP.
-
World champion Marquez crashes out of Indonesia MotoGP
-
Babis to meet Czech president after party tops parliamentary vote
-
Death toll from Indonesia school collapse rises to 37
-
OPEC+ meets with future oil production hanging in the balance
-
Dodgers down Phillies on Hernandez homer in MLB playoff series opener
-
Philadelphia down NYCFC to clinch MLS Supporters Shield
-
Syria selects members of first post-Assad parliament in contested process
NYSE - LSE
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately $2.0 million and $6.9, million, respectively. Revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively. Net loss for the three and nine months ended July 31, 2025 was approximately $0.2 million and $0.1 million, respectively, an earnings increase of approximately $0.1 million and $0.7 million when compared to the same periods last year, respectively.
"Over the past quarters, we have taken decisive steps to streamline our cost structure, prioritize core business segments, and exit less profitable areas. We believe these efforts have positioned the Company to capitalize on new opportunities with greater agility and focus. We are encouraged by the momentum building across our operations and are preparing for the immediate commencement of several significant projects. The Company remains committed to delivering long-term value to shareholders through disciplined execution," stated Mr. Sanchez Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
Y.Aukaiv--AMWN